Literature DB >> 26684814

Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates.

Abhishek Maiti1, Robert E Brown2, Paul G Corn3, Ravi Murthy4, Dhakshina Moorthy Ganeshan5, Apostolia M Tsimberidou6, Vivek Subbiah7.   

Abstract

Entities:  

Keywords:  Cell signaling pathways; Morphoproteomics; Refractory; Resistance; Resistant

Mesh：

Substances：

Year:  2015        PMID： 26684814      PMCID： PMC4783251          DOI： 10.1016/j.clgc.2015.11.004

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  37 in total

1.  The somatic genomic landscape of chromophobe renal cell carcinoma.

Authors:  Caleb F Davis; Christopher J Ricketts; Min Wang; Lixing Yang; Andrew D Cherniack; Hui Shen; Christian Buhay; Hyojin Kang; Sang Cheol Kim; Catherine C Fahey; Kathryn E Hacker; Gyan Bhanot; Dmitry A Gordenin; Andy Chu; Preethi H Gunaratne; Michael Biehl; Sahil Seth; Benny A Kaipparettu; Christopher A Bristow; Lawrence A Donehower; Eric M Wallen; Angela B Smith; Satish K Tickoo; Pheroze Tamboli; Victor Reuter; Laura S Schmidt; James J Hsieh; Toni K Choueiri; A Ari Hakimi; Lynda Chin; Matthew Meyerson; Raju Kucherlapati; Woong-Yang Park; A Gordon Robertson; Peter W Laird; Elizabeth P Henske; David J Kwiatkowski; Peter J Park; Margaret Morgan; Brian Shuch; Donna Muzny; David A Wheeler; W Marston Linehan; Richard A Gibbs; W Kimryn Rathmell; Chad J Creighton
Journal:  Cancer Cell       Date:  2014-08-21       Impact factor: 31.743

2.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

3.  Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.

Authors:  Chad Tang; Kenneth Hess; Denis Leonardo F Jardim; Debora De Melo Gagliato; Apostolia M Tsimberidou; Gerald Falchook; Siqing Fu; Filip Janku; Aung Naing; Sarina Piha-Paul; Vivek Subbiah; Jennifer Wheler; Ralph G Zinner; Razelle Kurzrock; Lee M Ellis; Funda Meric-Berstam; David S Hong
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

4.  Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution.

Authors:  Christopher G Przybycin; Angel M Cronin; Farbod Darvishian; Anuradha Gopalan; Hikmat A Al-Ahmadie; Samson W Fine; Ying-bei Chen; Melanie Bernstein; Paul Russo; Victor E Reuter; Satish K Tickoo
Journal:  Am J Surg Pathol       Date:  2011-07       Impact factor: 6.394

5.  Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.

Authors:  Toshiaki Shinojima; Mototsugu Oya; Atsushi Takayanagi; Ryuichi Mizuno; Nobuyoshi Shimizu; Masaru Murai
Journal:  Carcinogenesis       Date:  2006-08-18       Impact factor: 4.944

Review 6.  Aggressive variants of chromophobe renal cell carcinoma.

Authors:  A A Renshaw; E P Henske; K R Loughlin; C Shapiro; D S Weinberg
Journal:  Cancer       Date:  1996-10-15       Impact factor: 6.860

7.  Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine.

Authors:  Sahdeo Prasad; Vivek R Yadav; Bokyung Sung; Simone Reuter; Ramaswamy Kannappan; Amit Deorukhkar; Parmeswaran Diagaradjane; Caimiao Wei; Veerabhadran Baladandayuthapani; Sunil Krishnan; Sushovan Guha; Bharat B Aggarwal
Journal:  Clin Cancer Res       Date:  2012-07-25       Impact factor: 12.531

8.  Chromophobe renal cell carcinoma: analysis of 61 cases.

Authors:  Michaël Peyromaure; Vincent Misrai; Nicolas Thiounn; Annick Vieillefond; Marc Zerbib; Thierry A Flam; Bernard Debré
Journal:  Cancer       Date:  2004-04-01       Impact factor: 6.860

9.  The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells.

Authors:  Dongming Liang; Yuanyuan Ma; Jian Liu; Claes Goran Trope; Ruth Holm; Jahn M Nesland; Zhenhe Suo
Journal:  BMC Cancer       Date:  2012-05-29       Impact factor: 4.430

10.  Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.

Authors:  Vivek Subbiah; Robert E Brown; Jamie Buryanek; Jonathan Trent; Avi Ashkenazi; Roy Herbst; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2012-08-20       Impact factor: 6.009
View more
  1 in total

1.  Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.

Authors:  Jozefina Casuscelli; Maria F Becerra; Kenneth Seier; Brandon J Manley; Nicole Benfante; Almedina Redzematovic; Christian G Stief; James J Hsieh; Satish K Tickoo; Victor E Reuter; Jonathan A Coleman; Paul Russo; Irina Ostrovnaya; A Ari Hakimi
Journal:  Clin Genitourin Cancer       Date:  2019-06-26       Impact factor: 2.872
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.